Ubs Group Ag Dexcom Inc Call Options Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$64.0 - $116.06 $12.1 Million - $21.9 Million	188,740 Added 76.96%	434,000 $29.1 Million
Q2 2024 Aug 13, 2024	BUY	$110.31 - $140.45 $838,356 - $1.07 Million	7,600 Added 3.2%	245,260 $27.8 Million
Q1 2024 May 13, 2024	BUY	$114.22 - $140.1 $6.25 Million - $7.66 Million	54,700 Added 29.9%	237,660 $33 Million
Q4 2023 Feb 09, 2024	SELL	$75.49 - $124.16 $13.7 Million - $22.5 Million	-181,240 Reduced 49.76%	182,960 $22.7 Million
Q3 2023 Nov 09, 2023	BUY	$86.06 - $137.93 $14.9 Million - $23.8 Million	172,800 Added 90.28%	364,200 $34 Million
Q2 2023 Aug 11, 2023	BUY	$112.47 - $130.98 $13.6 Million - $15.8 Million	120,500 Added 169.96%	191,400 $24.6 Million
Q1 2023 May 12, 2023	SELL	$104.0 - $122.92 $2.76 Million - $3.26 Million	-26,522 Reduced 27.22%	70,900 $8.24 Million
Q4 2022 Feb 08, 2023	BUY	$84.98 - $122.67 $8.28 Million - $12 Million	97,422 New	97,422 $11 Million

1,013

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $29.5B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.